Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IOVA Iovance Biotherapeutics	$2.42 -1.2%	$2.33	$1.64 ▼ $12.51	$886.54M	0.88	15.98 million shs	9.10 million shs
PHAR Pharming Group	$13.97 +4.3%	$11.15	$6.73 ▼ $17.08	$918.17M	0.02	14,522 shs	4,343 shs
SOPH SOPHiA GENETICS	$3.33 -1.5%	$3.33	$2.58 ▼ $4.92	$228.42M	1	96,623 shs	42,811 shs
TRVI Trevi Therapeutics	$8.00 +7.8%	$6.87	$2.36 ▼ $8.78	$903.58M	0.58	1.42 million shs	9.49 million shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IOVA Iovance Biotherapeutics	-1.22%	-4.35%	-17.97%	+32.24%	-78.77%
PHAR Pharming Group	+3.07%	+14.32%	+39.70%	+31.79%	+72.04%
SOPH SOPHiA GENETICS	-1.48%	-6.98%	-0.89%	+16.03%	-7.76%
TRVI Trevi Therapeutics	+7.82%	+7.82%	+4.71%	+25.79%	+174.91%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IOVA Iovance Biotherapeutics	4.6098 of 5 stars	4.2	4.0	4.2	1.6	2.5	0.6
PHAR Pharming Group	2.3774 of 5 stars	3.5	3.0	0.0	3.0	0.0	0.6
SOPH SOPHiA GENETICS	2.7423 of 5 stars	3.5	5.0	0.0	2.1	0.0	0.6
TRVI Trevi Therapeutics	2.7032 of 5 stars	4.6	1.0	0.0	1.5	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IOVA Iovance Biotherapeutics	2.36	Hold	$11.90	391.74% Upside
PHAR Pharming Group	3.00	Buy	$30.00	114.75% Upside
SOPH SOPHiA GENETICS	3.00	Buy	$8.00	140.24% Upside
TRVI Trevi Therapeutics	3.20	Buy	$20.11	151.39% Upside

Current Analyst Ratings Breakdown

Latest SOPH, PHAR, IOVA, and TRVI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2025	TRVI Trevi Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$18.00
8/19/2025	IOVA Iovance Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
8/12/2025	IOVA Iovance Biotherapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
8/8/2025	IOVA Iovance Biotherapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$18.00 ➝ $14.00
8/8/2025	IOVA Iovance Biotherapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$25.00 ➝ $20.00
8/8/2025	TRVI Trevi Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Strong-Buy ➝ Strong-Buy	$29.00 ➝ $27.00
8/8/2025	TRVI Trevi Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$24.00 ➝ $22.00
7/23/2025	IOVA Iovance Biotherapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
7/15/2025	IOVA Iovance Biotherapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Sell
7/1/2025	TRVI Trevi Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$25.00
6/2/2025	TRVI Trevi Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IOVA Iovance Biotherapeutics	$164.07M	5.34	N/A	N/A	$1.93 per share	1.25
PHAR Pharming Group	$297.20M	3.22	$0.08 per share	180.78	$3.50 per share	3.99
SOPH SOPHiA GENETICS	$65.17M	3.45	N/A	N/A	$1.13 per share	2.95
TRVI Trevi Therapeutics	N/A	N/A	N/A	N/A	$1.63 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IOVA Iovance Biotherapeutics	-$372.18M	-$1.23	N/A	N/A	N/A	-161.44%	-52.87%	-41.31%	11/6/2025 (Estimated)
PHAR Pharming Group	-$11.84M	-$0.13	N/A	465.67	N/A	-2.19%	-3.31%	-1.78%	10/23/2025 (Estimated)
SOPH SOPHiA GENETICS	-$62.49M	-$0.44	N/A	N/A	N/A	-40.99%	-30.69%	-17.39%	11/4/2025 (Estimated)
TRVI Trevi Therapeutics	-$47.91M	-$0.42	N/A	N/A	N/A	N/A	-41.44%	-38.21%	11/5/2025 (Estimated)

Latest SOPH, PHAR, IOVA, and TRVI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	IOVA Iovance Biotherapeutics	-$0.29	-$0.33	-$0.04	-$0.33	$67.14 million	$59.95 million
8/7/2025	Q2 2025	TRVI Trevi Therapeutics	-$0.10	-$0.09	+$0.01	-$0.09	N/A	N/A
8/5/2025	Q2 2025	SOPH SOPHiA GENETICS	-$0.25	$0.33	+$0.58	$0.33	$17.49 million	$18.32 million
7/31/2025	Q2 2025	PHAR Pharming Group	-$0.10	$0.06	+$0.16	$0.06	$70.36 million	$93.20 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IOVA Iovance Biotherapeutics	N/A	N/A	N/A	N/A	N/A
PHAR Pharming Group	N/A	N/A	N/A	N/A	N/A
SOPH SOPHiA GENETICS	N/A	N/A	N/A	N/A	N/A
TRVI Trevi Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IOVA Iovance Biotherapeutics	N/A	3.27	2.89
PHAR Pharming Group	0.38	2.79	2.07
SOPH SOPHiA GENETICS	0.62	3.39	3.21
TRVI Trevi Therapeutics	N/A	22.42	22.42

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IOVA Iovance Biotherapeutics	77.03%
PHAR Pharming Group	0.03%
SOPH SOPHiA GENETICS	31.59%
TRVI Trevi Therapeutics	95.76%

Insider Ownership

Company	Insider Ownership
IOVA Iovance Biotherapeutics	10.30%
PHAR Pharming Group	2.07%
SOPH SOPHiA GENETICS	4.88%
TRVI Trevi Therapeutics	18.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IOVA Iovance Biotherapeutics	500	361.85 million	324.58 million	Optionable
PHAR Pharming Group	280	68.51 million	67.10 million	Not Optionable
SOPH SOPHiA GENETICS	520	67.58 million	64.28 million	Not Optionable
TRVI Trevi Therapeutics	20	121.78 million	99.49 million	Optionable

SOPH, PHAR, IOVA, and TRVI Headlines

Recent News About These Companies

Trevi Therapeutics to Participate in Upcoming September Conferences

1 hour ago | prnewswire.com

Trevi Therapeutics (NASDAQ:TRVI) Now Covered by Morgan Stanley

August 24, 2025 | americanbankingnews.com

Trevi Therapeutics (NASDAQ:TRVI) Coverage Initiated by Analysts at Morgan Stanley

August 23, 2025 | marketbeat.com

Morgan Stanley Initiates Coverage of Trevi Therapeutics (TRVI) with Overweight Recommendation

August 22, 2025 | msn.com

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives $20.38 Average Price Target from Analysts

August 20, 2025 | americanbankingnews.com

B. Riley Boosts Earnings Estimates for Trevi Therapeutics

August 19, 2025 | marketbeat.com

B. Riley Increases Earnings Estimates for Trevi Therapeutics

August 19, 2025 | americanbankingnews.com

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Shares Sold by XTX Topco Ltd

August 17, 2025 | marketbeat.com

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Rating of "Buy" from Analysts

August 16, 2025 | marketbeat.com

Persistent Asset Partners Ltd Makes New $260,000 Investment in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

August 13, 2025 | marketbeat.com

Informed Momentum Co LLC Invests $3.47 Million in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

August 13, 2025 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI), DENTSPLY SIRONA (XRAY) and Arrowhead Pharmaceuticals (ARWR)

August 13, 2025 | theglobeandmail.com

Trevi Therapeutics: Optimism Amid Earnings Call Insights

August 13, 2025 | msn.com

HC Wainwright Analysts Increase Earnings Estimates for TRVI

August 12, 2025 | marketbeat.com

Trevi Therapeutics (NASDAQ:TRVI) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS

August 11, 2025 | marketbeat.com

Raymond James Financial Issues Pessimistic Forecast for Trevi Therapeutics (NASDAQ:TRVI) Stock Price

August 10, 2025 | marketbeat.com

Trevi Therapeutics (NASDAQ:TRVI) Is In A Good Position To Deliver On Growth Plans

August 10, 2025 | finance.yahoo.com

Needham & Company LLC Lowers Trevi Therapeutics (NASDAQ:TRVI) Price Target to $22.00

August 9, 2025 | marketbeat.com

Trevi Therapeutics, Inc. (TRVI) Q2 2025 Earnings Call Transcript

August 8, 2025 | seekingalpha.com

Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

August 7, 2025 | prnewswire.com

41,987 Shares in Trevi Therapeutics, Inc. (NASDAQ:TRVI) Bought by BIT Capital GmbH

August 4, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

SOPH, PHAR, IOVA, and TRVI Company Descriptions

Iovance Biotherapeutics NASDAQ:IOVA

$2.42 -0.03 (-1.22%)

Closing price 08/27/2025 04:00 PM Eastern

Extended Trading

$2.42 0.00 (0.00%)

As of 07:25 AM Eastern

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Pharming Group NASDAQ:PHAR

$13.97 +0.57 (+4.25%)

Closing price 08/27/2025 03:46 PM Eastern

Extended Trading

$14.31 +0.34 (+2.43%)

As of 07:48 AM Eastern

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

SOPHiA GENETICS NASDAQ:SOPH

$3.33 -0.05 (-1.48%)

Closing price 08/27/2025 04:00 PM Eastern

Extended Trading

$3.34 +0.02 (+0.45%)

As of 08/27/2025 04:10 PM Eastern

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.

Trevi Therapeutics NASDAQ:TRVI

$8.00 +0.58 (+7.82%)

Closing price 08/27/2025 04:00 PM Eastern

Extended Trading

$8.15 +0.15 (+1.94%)

As of 07:52 AM Eastern

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time